Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
|Articles|January 1, 2008
Ideal length of androgen ablation for treatment of prostate cancer still debated
Although the observation is awaiting confirmation by more definitive data, it may be that in a select group of radiation-treated prostate cancer patients, 6 months of androgen ablation is as effective as a 3-year course of the adjuvant therapy in terms of cancer-specific survival.
Advertisement
Advertisement
Related to this article
The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Advertisement
Advertisement
Trending on Urology Times
1
Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC
2
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
5